David Hirsch - Tricida Independent Director
| TCDADelisted Stock | USD 0.01 0.0001 0.71% |
Director
Dr. David Hirsch M.D., Ph.D., is Independent Director of the Company. He has served as a member of our board of directors since July 2016. Since 2007, Dr. Hirsch has served as a Founder and Managing Director at Longitude Capital Management, an affiliate of one of our principal stockholders, where he focuses on investments in biotechnology. From 2005 to 2006, Dr. Hirsch was Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot Ventures, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey Co. Dr. Hirsch currently serves on the boards of directors of the following public companies Collegium Pharmaceutical, Inc., since 2012, and Molecular Templates, Inc., since 2017. Dr. Hirsch also serves on the boards of directors of the following private companies Inflazome, Ltd., Poseida Therapeutics, Inc., Rapid Micro Biosystems, Inc., and Velicept Therapeutics, Inc., and Dr. Hirsch previously served on the boards of directors of Civitas Therapeutics, Inc., Precision Therapeutics, Inc., and Zavante Therapeutics, Inc since 2016.
| Age | 47 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 415 429 7800 |
| Web | https://www.tricida.com |
Tricida Management Efficiency
The company has return on total asset (ROA) of (0.6011) % which means that it has lost $0.6011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.2371) %, meaning that it created substantial loss on money invested by shareholders. Tricida's management efficiency ratios could be used to measure how well Tricida manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 127.51 M in liabilities. Tricida has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Tricida until it has trouble settling it off, either with new capital or with free cash flow. So, Tricida's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Tricida sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Tricida to invest in growth at high rates of return. When we think about Tricida's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Price | Eldorado Gold Corp | 63 | |
| David Denison | BCE Inc | 68 | |
| Paul Weiss | BCE Inc | 71 | |
| Robert Brown | BCE Inc | 74 | |
| John Webster | Eldorado Gold Corp | 65 | |
| Monique Leroux | BCE Inc | 67 | |
| Cornell Wright | BCE Inc | 47 | |
| Barbara Scherer | NETGEAR | 62 | |
| Jeffrey Graham | NETGEAR | 62 | |
| Karen Sheriff | BCE Inc | 63 | |
| Pamela Gibson | Eldorado Gold Corp | 66 | |
| Jonathan Rubenstein | Eldorado Gold Corp | 67 | |
| Ross Cory | Eldorado Gold Corp | 58 | |
| Calin Rovinescu | BCE Inc | 65 | |
| Jennifer Tory | BCE Inc | 65 | |
| Julie Shimer | NETGEAR | 65 | |
| Ian Greenberg | BCE Inc | 77 | |
| Gregory Rossmann | NETGEAR | 56 | |
| Geoffrey Handley | Eldorado Gold Corp | 68 | |
| Timothy Godwin | NETGEAR | 64 | |
| Jef Graham | NETGEAR | 60 | |
Management Performance
| Return On Equity | -3.24 | |||
| Return On Asset | -0.6 |
Tricida Leadership Team
Elected by the shareholders, the Tricida's board of directors comprises two types of representatives: Tricida inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tricida. The board's role is to monitor Tricida's management team and ensure that shareholders' interests are well served. Tricida's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tricida's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jerry Buysse, Senior Vice President Chief Scientific Officer | ||
| Wilhelm Stahl, Senior Vice President CTO | ||
| Robert Alpern, Independent Director | ||
| Edward Hejlek, Senior Vice President General Counsel | ||
| Geoffrey Parker, CFO, Senior Vice President | ||
| David Hirsch, Independent Director | ||
| JD Esq, Ex Property | ||
| Claire Lockey, Senior Vice President and Chief Development Officer | ||
| David Bonita, Chairman of the Board | ||
| Sandra Coufal, Independent Director | ||
| Gerrit Klaerner, President CEO, Member of the Board of Directors | ||
| Annie Yoshiyama, VP Officer | ||
| Jeroen Beek, Chief Commercial Officer and Senior Vice President | ||
| Kathryn Falberg, Independent Director | ||
| Klaus Veitinger, Independent Chairman of the Board | ||
| Dawn Parsell, Senior Vice President - Clinical Development | ||
| Susannah Cantrell, Senior Vice President Chief Commercial Officer | ||
| Robert JD, Company VP | ||
| Jackie Cossmon, VP Communications |
Tricida Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tricida a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.24 | |||
| Return On Asset | -0.6 | |||
| Current Valuation | 140.46 M | |||
| Shares Outstanding | 58.03 M | |||
| Shares Owned By Insiders | 8.01 % | |||
| Shares Owned By Institutions | 64.71 % | |||
| Number Of Shares Shorted | 10.53 M | |||
| Price To Book | 2,324 X | |||
| EBITDA | (158.52 M) | |||
| Net Income | (176.57 M) |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tricida information on this page should be used as a complementary analysis to other Tricida's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Tricida Stock
If you are still planning to invest in Tricida check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tricida's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |